Diagnostic Accuracy of Dynamic Contrast-Enhanced MR Imaging Using a Phase-Derived Vascular Input Function in the Preoperative Grading of Gliomas


doi: https://doi.org/10.3174/ajnr.A3012
http://www.ajnr.org/content/33/8/1539
Diagnostic Accuracy of Dynamic Contrast-Enhanced MR Imaging Using a Phase-Derived Vascular Input Function in the Preoperative Grading of Gliomas

**BACKGROUND AND PURPOSE:** The accuracy of tumor plasma volume and $K_{trans}$ estimates obtained with DCE MR imaging may have inaccuracies introduced by a poor estimation of the VIF. In this study, we evaluated the diagnostic accuracy of a novel technique by using a phase-derived VIF and “bookend” T1 measurements in the preoperative grading of patients with suspected gliomas.

**MATERIALS AND METHODS:** This prospective study included 46 patients with a new pathologically confirmed diagnosis of glioma. Both magnitude and phase images were acquired during DCE MR imaging for estimates of $K_{trans}$, $Vp$, and $Vt$ (calculated from a phase-derived VIF and bookend T1 measurements) as well as $K_{trans}$, $Vp$, and $Vt$ (calculated from a magnitude-derived VIF without T1 measurements).

**RESULTS:** Median $K_{trans}$, $Vp$, and $Vt$ values were 0.0041 minutes$^{-1}$ (95% CI, 0.0006–0.033), 0.031 minutes$^{-1}$ (0.011–0.150), and 0.088 minutes$^{-1}$ (0.069–0.110) for grade II, III, and IV gliomas, respectively ($P < 0.05$ for each). Median $Vp$, $Vt$, and $Vp$ values were 0.64 mL/100 g (0.06–1.40), 0.98 mL/100 g (0.34–2.20), and 2.16 mL/100 g (1.8–3.1) with $P = 0.15$ between grade II and III gliomas and $P = 0.015$ between grade III and IV gliomas. In differentiating low-grade from high-grade gliomas, AUCs for $K_{trans}$, $Vp$, $Vt$, $K_{trans}$, $Vp$, and $Vt$ were 0.87 (0.73–1), 0.84 (0.69–0.98), 0.81 (0.59–1), and 0.84 (0.66–0.91). The differences between the AUCs were not statistically significant.

**CONCLUSIONS:** $K_{trans}$, $Vp$, and $Vt$ are parameters that can help in differentiating low-grade from high-grade gliomas.

**ABBREVIATIONS:** AUC = area under the receiver operating characteristic curve; $C_{(t)}$ = tissue contrast concentration curve with time; CI = confidence interval; CV = coefficient of variation; DCE = dynamic contrast-enhanced; $K_{trans}$ = volume transfer coefficient obtained from phase-derived vascular input function; $K_{trans}$ = volume transfer coefficient obtained from magnitude-derived vascular input function; NPV = negative predictive value; PPV = positive predictive value; $R_1$ = rate of longitudinal relaxation; $R_2^*$ = observed rate of transverse relaxation; ROC = receiver operating characteristic analysis; $T_1$ = longitudinal relaxation time; $Vp$, $Vt$ = plasma volume obtained from magnitude-derived vascular input function; VIF = vascular input function; $Vp$, $Vt$ = plasma volume obtained from phase-derived vascular input function.

Contrast-enhanced anatomic MR imaging is not always accurate in differentiating high-grade gliomas from low-grade gliomas. The presence of contrast enhancement is more common in higher grade gliomas but is not infrequently found in low-grade tumors. Physiologic imaging such as perfusion MR imaging has been used recently to evaluate angiogenesis, which is important for both the growth and metastasis of malignant tumors. The 2 most common MR perfusion techniques used in clinical practice are dynamic susceptibility-weighted contrast-enhanced imaging and DCE imaging. Following an intravenous injection of a Gd-based contrast agent, dynamic susceptibility-weighted contrast-enhanced imaging measures the change in $R_1$ during the first pass of the bolus, while DCE imaging measures the changes in $R_1$ during both the first pass and washout phases.

While DCE perfusion might be more accurate than dynamic susceptibility-weighted contrast-enhanced imaging in the measurement of parameters such as cerebral blood volume and permeability index, DCE usually requires more complex data acquisition and analysis. First, determination of $T_1$ values in brain tissue before contrast injection is now usually done for calculation of $C_{(t)}$ from changes in $R_1$ following bolus injection. Additional measurements of $T_1$ values following contrast injection, “bookend” measurements, have also been performed to improve the accuracy of DCE parameters. Second, an accurate VIF is needed but is difficult to obtain because the relationship between MR signal intensity and absolute contrast concentration is not always linear and might be compromised by inflow. Recently, several authors have proposed the use of phase information to derive the VIF. It is known that if a vessel is approximately parallel to the magnetic field, changes in gadolinium-based contrast agent concentration vary linearly with phase.
Because phase images can be acquired at the same time as magnitude images, no additional imaging is required.

In this study, we evaluated the diagnostic accuracy of DCE MR imaging parameters by using phase-derived VIF and bookend T1 measurements in the preoperative grading of patients with suspected gliomas. We compared this technique with a simpler pharmacokinetic analysis by using magnitude-derived VIF without T1 mapping.

**Materials and Methods**

**Subjects**

All examinations were conducted in accordance with the guidelines of our institution for human research, and written informed consent was obtained from all participating subjects. All adult patients presenting at the Ottawa Hospital with a newly diagnosed brain lesion compatible with a glioma between December 2008 and March 2010 were included in this prospective study. We set the following exclusion criteria: pregnancy, renal failure, and a known history of allergy to gadolinium-based MR imaging contrast agent. Following the MR imaging examination, patients underwent surgery with biopsy or surgical resection of the lesion. The average time interval between the MR imaging examination and surgery was 12.5 days. Histopathologic diagnosis was provided by an experienced neuropathologist (J.W., 12 years of experience, or G.H.J., 23 years of experience) by using the World Health Organization classification.

**MR Imaging Acquisition**

All MR imaging data were acquired by using either a 1.5T (Symphony; Siemens, Erlangen, Germany) or a 3T clinical scanner (Trio, Siemens). Anatomic imaging was performed by using standard sagittal T1-weighted and axial T1-weighted pre- and post-DCE contrast injection; and axial FLAIR, axial T2, and coronal T1 post-DCE contrast injection.

At 1.5T, DCE MR imaging was performed by using a 2D fast low-angle shot pulse sequence (5 axial sections, TR = 45 ms, TE = 2.1, 5.5 ms, flip angle = 90°, matrix = 96 × 128, FOV = 17 × 23 cm², section thickness = 5 mm, Δt = 2.2 seconds). 2D fast low-angle shot was used for dynamic imaging on the 1.5T scanner because of hardware limitations. The desired temporal resolution (Δt < 3 seconds) was only achievable with the 2D sequences. At 3T, a 3D fast low-angle shot sequence was used (18 axial sections, TR = 6.5 ms, TE = 1.7, 3.9 ms, flip angle = 30°, matrix = 96 × 128, FOV = 23 cm², section thickness = 5 mm, Δt = 2.9 seconds). The 2D and 3D fast low-angle shot sequences generated phase images in addition to the standard magnitude images. Both before and after the DCE MR imaging, a series of gradient-echo images was acquired, which enabled the calculation of T1 maps. 3D fast low-angle shot images (TR = 50 ms, TE = 2.2 ms, flip angle = 10°, 20°, 40°, 70°) were obtained at 1.5T, and 3D volumetric interpolated breathhold examination images (TR = 20 ms, TE = 1.2 ms, flip angle = 4°, 25°) were used at 3T. 3D sequences were used on both scanners for T1 mapping, to minimize section profile effects. For T1 mapping on the 3T scanner, volumetric interpolated breathhold examination was used instead of fast low-angle shot, though the contrast mechanisms of these 2 sequences are very similar (T1-weighted spoiled gradient-echo). A shorter TR and fewer flip angles were used for T1 mapping at 3T to reduce scanning time.
This was possible due to the additional signal intensity–to-noise ratio available on that machine.

Gadopentetate dimeglumine (Magnevist; Bayer Schering, Berlin, Germany) was injected at 0.1 mmol/kg and 4 mL/s, beginning 40 seconds after the start of the scan. The duration of the DCE sequence was 220 seconds.

**Pharmacokinetic Modeling**

Phase-Derived VIF with Bookend T1 Correction. Voxel wise maps of C(T) were calculated in 2 steps. First, the double echo was used to extrapolate all magnitude signals to TE = 0 ms, thereby reducing T2* effects. Second, the pre- and post-DCE T1 maps were combined with the extrapolated tissue signal-intensity-versus-time curve by using standard signal-intensity equations to compute C(T). The VIF was calculated from the superior sagittal sinus by measuring the change in phase as a function of time, taking into account the angle of each vessel segment relative to the main magnetic field. This was possible due to the additional signal intensity–to-noise ratio available on that machine.

**Table 2: Median values of the maximal perfusion parameters and coefficient of variation for different grades of gliomas using a 3D gradient-recalled echo sequence on a 3T MR scanner**

<table>
<thead>
<tr>
<th>No.</th>
<th>K&lt;sup&gt;trans&lt;/sup&gt; <em>V</em> (min&lt;sup&gt;-1&lt;/sup&gt;) (95% CI)</th>
<th>CV (%)</th>
<th>K&lt;sup&gt;trans&lt;/sup&gt; <em>SI</em> (min&lt;sup&gt;-1&lt;/sup&gt;) (95% CI)</th>
<th>CV (%)</th>
<th>V&lt;sub&gt;p&lt;/sub&gt; <em>V</em> (mL/100 g) (95% CI)</th>
<th>CV (%)</th>
<th>V&lt;sub&gt;p&lt;/sub&gt; <em>SI</em> (mL/100 g) (95% CI)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 2</td>
<td>8</td>
<td>0.0096 (0.0076–0.012)</td>
<td>153</td>
<td>0.0036 (0.00056–0.017)</td>
<td>210</td>
<td>0.66 (0.091–1.55)</td>
<td>91</td>
<td>3.35 (0.22–6.9)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>4</td>
<td>0.020</td>
<td>142</td>
<td>0.0052</td>
<td>191</td>
<td>1.37</td>
<td>105</td>
<td>2.8</td>
</tr>
<tr>
<td>Grade 4</td>
<td>19</td>
<td>0.10 (0.072–0.12)</td>
<td>46</td>
<td>0.13 (0.072–0.22)</td>
<td>85</td>
<td>2.0 (1.7–3.1)</td>
<td>78</td>
<td>8.8 (5.3–14)</td>
</tr>
</tbody>
</table>

**Statistical Analysis**

All data were analyzed by using MedCalc for Windows, Version 11.5 (MedCalc Software, Mariakerke, Belgium). There were 6 components to the statistical analysis: 1) calculation of sensitivity and specificity for each reader by using anatomic MR imaging to grade gliomas, 2) assessment of inter-reader reliability by using the κ statistic. 3) tests for difference in maximum V<sub>p</sub> and K<sup>trans</sup> values according to grade by using the Mann-Whitney U test, 4) tests for difference in maximum V<sub>p</sub> and K<sup>trans</sup> values according to the MR imaging acquisition method (2D-versus-3D fast low-angle shot) by using the Mann-Whitney U test, 5) ROC analysis for V<sub>p</sub> and K<sup>trans</sup> in grading gliomas by using each method, and 6) Bland-Altman analysis of within-subject reproducibility of V<sub>p</sub> and K<sup>trans</sup> values by using both methods and testing for difference between values by using a paired Wilcoxon test.

**Results**

**Participants**

During the study period, a total of 60 patients presented with a newly diagnosed brain lesion and had DCE MR imaging. Six patients did not have any surgery, 6 patients had a pathologic diagnosis other than glioma following surgery (1 normal brain tissue, 4 metastasis, 1 supratentorial ependymoma grade III), and 2 patients had missing data from MR perfusion imaging. Forty-six patients with a newly pathologically proved diagnosis of glioma were included in the analysis (9 grade II, 9 grade III, 28 grade IV) with 42 astrocytomas, 3 oligoastrocytomas, and 1 oligodendroglioma.

**Accuracy of Conventional Imaging for Distinguishing Low-Grade from High-Grade Gliomas**

In distinguishing low-grade (grade II) from high-grade gliomas (grades III and IV), reader 1 had a sensitivity of 97% and a specificity of 67% (PPV = 92%, NPV = 86%), while reader 2 achieved a sensitivity of 95% and a specificity of 67% (PPV = 92%, NPV = 75%). There was substantial agreement between the 2 readers (κ = 0.76, 95% CI, 0.50–1.0).

**V<sub>p</sub> and K<sup>trans</sup> Values According to Glioma Grades**

The median K<sup>trans</sup> and V<sub>p</sub> values for each glioma grade and for each MR imaging scanner are summarized in Tables 1–3 and
depicted graphically in Fig 2. There was a statistical difference in median $K_{trans}$ estimates between grades III and IV (Table 4). The difference in $K_{trans}$ between grade II and III gliomas is near statistical significance ($P = .050$) and becomes significant if we exclude patients who had a pathologic diagnosis from a stereotactic biopsy and not from a surgical resection ($P = .0047$).

Median $V_p$ values also increased with higher glioma grade. This difference was not statistically significant between grades II and III but was significant between grades III and IV (Table 4). The intersubject CVs were higher for low-grade gliomas than for high-grade gliomas.

With the magnitude-derived VIF approach, $K_{trans}$ values and $V_p$ values also differed on the basis of glioma grade (Tables 1–3) (Fig 2A–D). There was a statistically significant difference found between grades III and IV but not between grades II and grade III (Table 4).

$V_p$ and $K_{trans}$ Values According to MR Imaging Acquisition Method (2D versus 3D)

In general, 3D acquisitions had lower intersubject CVs for both $K_{trans}$ and $V_p$ than 2D acquisitions. $K_{trans}$ values had lower intersubject CVs than $K_{trans}$ SI, $V_p$ values had lower CVs than $V_p$ SI except for grade III gliomas (Tables 1–3).

In the group of 9 patients with grade II gliomas, comparison between values obtained from the 2D fast low-angle shot sequence (1.5T scanner) and 3D fast low-angle shot sequence (3T scanner) was not possible because only 1 patient was scanned on the 3T scanner. For patients with grade III, no statistical difference could be found between perfusion parameters obtained with 2D and 3D acquisition methods, but for grade IV gliomas, a near statistical difference was found with $K_{trans}$ ($P = .058$) (Table 4).

Accuracy of DCE MR Perfusion for Distinguishing Glioma Grades by using ROC

In distinguishing low-grade (II) from high-grade gliomas (III+IV), the highest AUC corresponded to $K_{trans}$, followed by $V_p$, $V_p$ SI, and $K_{trans}$ SI (Fig 3A, B) (Table 5). However, the differences between the AUCs for $K_{trans}$ versus $K_{trans}$ SI and for $V_p$ versus $V_p$ SI did not reach statistical significance ($P = .18$ and $P = .87$, respectively). Using a threshold of $K_{trans} > 0.018$ minutes $^{-1}$, we achieved a sensitivity of 89% with a specificity of 84%.
and a specificity of 75% (PPV = 94%, NPV = 62%). With a threshold of \( V_{p, \varphi} > 1.4 \) mL/100 g, sensitivity was 68% and specificity was 89% (PPV = 96%, NPV = 40%).

In distinguishing grade III from grade IV gliomas, the AUCs associated with \( V_{p, \varphi} \) and \( V_{p, SI} \) were slightly higher than those obtained for \( K^{trans}_{SI} \) and \( K^{trans} \varphi \) (Table 5). However, the differences between the AUCs for \( V_{p, SI} \) and \( V_{p, \varphi} \) and for \( K^{trans}_{SI} \) and \( K^{trans} \varphi \) were not statistically significant (\( P = .43 \) and \( P = .38 \) respectively). Using a threshold of \( V_{p, \varphi} > 1.75 \) mL/100 g, sensitivity was 68% and specificity was 88% (PPV = 95%, NPV = 44%) for differentiating grade IV from grade III gliomas.

**Within-Subject Reproducibility of \( V_{p} \) and \( K^{trans} \) Values by using Magnitude-versus-Phase Techniques**

The mean absolute difference between \( K^{trans}_{SI} \) and \( K^{trans} \varphi \) was 0.06 minutes\(^{-1}\) with limits of agreement of \( \pm 0.22 \) minutes\(^{-1}\), which was statistically different (\( P = .001 \)) (Fig 4A). The difference in percentage was 17%, with limits of agreement of \( \pm 191\% \). The mean absolute difference between \( V_{p, SI} \) and \( V_{p, \varphi} \) was 6.7 mL/100 g, with limits of agreement of \( \pm 15.4 \) mL/100 g, which was statistically different (\( P < .0001 \)) (Fig 4B). The difference in percentage was 103% with limits of agreement of \( \pm 134\% \). Agreement between \( K^{trans}_{SI} \) and \( K^{trans} \varphi \) and between \( V_{p, SI} \) and \( V_{p, \varphi} \) is dependent on the magnitude of measurements, with a good agreement at low values and a poor agreement at high values.

**Discussion**

Dynamic susceptibility-weighted contrast-enhanced MR perfusion is currently the most frequently used technique to measure CBV in cerebral gliomas, primarily due to the robustness of the technique. Several authors have demonstrated a high degree of correlation between histologic grades and CBV.\(^1-11\) However, CBV measurements from dynamic susceptibility-weighted contrast-enhanced require correction for leakage in areas of blood-brain disruption in tumors and are prone to susceptibility artifacts arising from hemorrhage, calcification, or bone.\(^12-14\)

DCE MR imaging is a T1-weighted technique, which is, as a consequence, less sensitive to susceptibility artifacts. It has been introduced more recently to quantify the absolute plasma volume and the volume transfer coefficient, which measures the degree of contrast leakage from the intravascular to the extravascular compartment. Although there have been numerous studies using DCE MR perfusion to grade tumors, it is somewhat difficult to compare published values because different research centers have different MR imaging acquisition techniques and postprocessing algorithms. In our study, we compared 2 methods: 1 that assumes there is linearity between changes in contrast concentration and signal intensity and a more novel approach that uses pre- and postcontrast T1 quantification and a vascular input function derived from MR phase images.

The \( K^{trans} \) values obtained by using the magnitude-VIF (\( K^{trans}_{SI} \)) were within the range of those published in 1 of the first studies using DCE MR imaging for grading gliomas by Roberts et al\(^1\), which used changes in signal intensity to calculate perfusion values.\(^8\) The authors obtained a median transfer constant for grade IV gliomas of 0.107 minutes\(^{-1}\), which is similar to our \( K^{trans}_{SI} \) value of 0.15 minutes\(^{-1}\). They also found a statistically significant difference between the transfer constants for grade III and IV gliomas but not between grades II and III, which is consistent with our findings. The median fractional blood volume for grade IV gliomas reported by Roberts et al was only 6%, which (assuming a hematocrit of 0.45) is lower than the 17% value corresponding to our \( V_{p, SI} \) value of 9.4 mL/100 g. They did not find a correlation between fractional blood volume and tumor grade, whereas we found a statistical difference between \( V_{p, SI} \) values for grade III and IV gliomas but not between grades II and III gliomas. Their protocol was slightly different from ours because they had low temporal resolution and used a Patlak analysis, whereas our images were acquired with high temporal resolution and analyzed by deconvolution of the VIF.

A more recent study by Patankar et al\(^1\) used precontrast T1 mapping and a magnitude-derived VIF to demonstrate that CBV can be used to distinguish high-grade and low-grade gliomas. The authors reported CBV values of 1.3%, 3%, and 4% for grade II, III, and IV gliomas, respectively. These results are in the range of our \( V_{p, \varphi} \) values of 0.64 mL/100 g (CBV = 1.2%), 0.98 mL/100 g (CBV = 1.78%), and 2.16 mL/100 g (CBV = 3.9%) for grade II, III, and IV gliomas, respectively. In contrast to Patankar et al, we did not find a significant difference in \( V_{p, \varphi} \) between grade II and III gliomas, perhaps due to inaccurate pathologic grading from biopsy. Two patients in our low-grade glioma group had very high perfusion parameters but their gliomas were classified as grade II following biopsy. There was probably a sampling bias because the lesions

**Fig 2.** A, ROC for comparison of maximal \( K^{trans}_{\varphi} \) and \( K^{trans}_{SI} \) for differentiation of low-grade from high-grade gliomas. B, ROC for comparison of \( V_{p, \varphi} \) and \( V_{p, SI} \) in differentiating low-grade and high-grade gliomas.
enhanced strongly and the patients died shortly after surgery. The other study obtained $K_{\text{trans}}$ values of 0.0007 minutes$^{-1}$, 0.0185 minutes$^{-1}$, and 0.0250 minutes$^{-1}$ for grade II, III, and IV gliomas, respectively, which are lower than our values and could be due to the use of a different pharmacokinetic model. The authors did not find a statistically significant difference between either grade II and III or grade III and IV gliomas.

In agreement with the published literature, our study showed that $V_\text{p}$ and $K_{\text{trans}}$ values are dependent on the assumptions made for the conversion of signal intensity to contrast concentration and the choice of vascular input function.\(^8\) Within each subject, there is a bias toward lower values by using the phase method compared with the signal-intensity method. This bias was less important for $K_{\text{trans}}$ than for $V_\text{p}$ (17% versus 103%), but the limits of agreement are larger (SD of 191% versus 134%). Within each glioma group, the reproducibility of $K_{\text{trans}}$ was better than that of $K_{\text{trans}}$. The diagnostic accuracy of $K_{\text{trans}}$ was also slightly better (though not statistically significant) than $K_{\text{trans}}$ and comparable with conventional MR imaging in our study.

The use of a phase-derived VIF has several advantages over techniques that use a magnitude-derived VIF: Phase does not saturate at high contrast concentration and is less sensitive to inflow effects.\(^8\) For that reason, some authors have proposed performing 2 injections of 0.05 mmol/kg of gadolinium for DCE MR imaging to minimize the error arising from the conversion of signal intensity to gadolinium concentration from magnitude images.\(^6\) While saturation of signal intensity could lead to an underestimation of the contrast agent concentration, the presence of inflow effects could lead to an overestimation.\(^7\) Our magnitude-VIF based $K_{\text{trans}}$ and $V_\text{p}$ estimates were higher than those derived from the phase method. This might be due to an underestimation of the contrast agent concentration in the VIF. We obtained lower coefficients of variation for the perfusion values with the phase method. This is expected because phase-derived VIF is less sensitive to inflow effects.\(^9\) Even though 3D gradient-recalled echo sequences are less sensitive to inflow than 2D gradient-recalled echo, perfusion values obtained with the phase method also had lower coefficients of variation than the ones obtained from the SI method. The use of bookend T1 measurements with the phase technique could also have contributed to an improvement in the calculations of perfusion values because this technique can presumably provide more accurate estimation of the gadolinium concentration in tumors.\(^4\)

The disadvantages of using a phase-derived VIF are the following: It requires additional time to process phase images even though they are freely available from the scanner. Measurements can be biased if there is a drift of the phase signal intensity, making estimation of the steady-state baseline less reliable.\(^8\) In certain circumstances, such as when the signal intensity—to-noise-ratio is low, the signal-intensity approach might even yield more useful perfusion measurements because less processing of the data is required than for a phase- or magnitude-based approach, which requires the conversion to gadolinium concentration by using T1 measurements obtained at baseline.\(^9\)

We note 3 potential limitations to our findings: First, the small number of patients with grade II and III gliomas limited our power to detect a statistical difference in the diagnostic accuracy of our novel phase-VIF technique compared with the more conventional magnitude-VIF method. Second, because some patients with grade II gliomas had only a biopsy, a misclassification could have resulted in including these cases. We suspect this surgical sampling bias contributed to the very high coefficients of variation for perfusion parameters in low-grade tumors. Third, there might be a measurement bias due to methodologic differences between the 2D and 3D techniques. However, we do not believe that the different pulse sequences and field strengths had a major systematic effect on pharmacokinetic parameters calculated from phase-derived VIFs with bookend T1 correction. The bookend technique has inherent self-correcting and self-consistency mechanisms that depend little on pulse sequence parameters or field strength. There was not any statistically significant difference in steady-state gadolinium concentrations in tumor between the 2D and 3D acquisitions (data not shown). For the phase-derived VIFs, changes in pulse-sequence parameters and field strength theoretically should not introduce systematic errors either. We found no statistically significant difference in peak gadolinium concentration, area under the first pass, or steady-state gadolinium concentration between the 2D and 3D acquisitions (data not shown). Therefore, it is not clear why there was a near-significant difference in $K_{\text{trans}}$ values between the 2D and 3D acquisitions for grade IV gliomas. This is perhaps due to the inherent biologic heterogeneity of these tumors and the subtlety of effects related to the different acquisitions. The similarity of pharmacokinetic parameters between 2D and 3D acquisitions for magnitude-derived VIFs with no T1 correction also suggests that the relationship between signal intensity and gadolinium concentration was consistent and reasonably linear for each of the 2 acquisitions.

**Conclusions**

We have shown that $K_{\text{trans}}$ and $V_\text{p}$ values obtained by using the phase-derived VIF with the bookend T1 measurement technique can be used to differentiate low-grade from high-grade gliomas. This novel method can be implemented by using either a 2D or a 3D sequence, but in general, the use of a 3D sequence resulted in better intersubject reproducibility. This approach might improve the diagnostic accuracy of preoperative glioma grading compared with other MR imaging methods currently used to assess tumor perfusion.

**Appendix**

Kinetic modeling theory was performed by using a 2-compartment extended Tofts model implemented in the nordicICE software (NordicNeuroLab).\(^20\)-\(^22\) The contrast agent is assumed to be distributed in the plasma volume ($V_\text{p}$) initially with a time-dependent leakage to the extravascular, extracellular space. $K_{\text{trans}}$ is the transfer coefficient from the plasma volume to the extravascular, extracellular space, and $K_{ep}$ is the rate constant back to the...
plasma space. Given the tissue concentration curve \( C_T(t) \) and the vascular input function \( C_P(t) \), this equation can be solved by using the following convolution integral:

\[
C_T(t) = \int_0^t C_P(\tau) e^{-K_{ep}(t-\tau)}d\tau \times V_P C_{\rho}(t).
\]

When deconvolution of the VIF is performed, \( K_{trans} \) and \( K_{ep} \) values are obtained in units of inverse minutes, whereas \( V_P \) is a relative fraction.

\( C_T(t) \) is not measured directly but is derived from changes in MR signal intensity due to gadolinium injection. For the simpler pharmacokinetic approach by using magnitude images only, we assumed that signal intensity varied linearly with \( C_T(t) \). Because this assumption might not be valid at a high concentration of gadolinium, we used the bookend technique for our novel method with a phase-derived VIF. The bookend technique measured \( T_{1pre} \) and \( T_{1post} \) values, which allowed computation of \( C_T(t) \) from changes in signal intensity.

Disclosures: Thanh Binh Nguyen—UNRELATED: Consultancy: Bayer HealthCare, Comments: I have acted as a paid consultant for Bayer HealthCare in 2 projects unrelated to the submitted work. Grants/Grants Pending: Bayer HealthCare, Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Bayer HealthCare, Carlos Torres—UNRELATED: Multiple Sclerosis Society of Canada,* Gerard H. Jansen—UNRELATED: Board Membership: Elekta, Comments: payment only of travel costs. Elekta is a laboratory informatics company. The money paid to me is not in any way connected to my work on the publication. Consultancy: Public Health Agency of Canada, Comments: This relates to other work I perform for the Canadian government related to Creutzfeldt-Jakob disease. The money paid to me is not in any way connected to my work on the publication. Jean-Michel Caulier—UNRELATED: Employment: Cancer Care Ontario, Comments: clinical fees for service activities. Matthew Hogan—UNRELATED: Grants/Grants Pending: Canadian Foundation for Innovation,*Money paid to the institution.

References